Apyx Medical (APYX)

The company is best known for Renuvion, a platform that combines radiofrequency energy with helium plasma. Renuvion is marketed for aesthetic and surgical applications where controlled heat delivery is important, including procedures performed after liposuction or as part of body-contouring and skin-tightening workflows. Apyx also offers J-Plasma technology, which is designed to give surgeons a focused energy tool for cutting, coagulation, and tissue management with a high degree of control.

Apyx reports its business through two main areas: Surgical Aesthetics and Original Equipment Manufacturing. Surgical Aesthetics is the company’s core revenue driver and includes its branded generators, handpieces, and related consumables. The OEM business supplies components and technology to other medical device manufacturers, giving Apyx an additional channel for its energy-platform expertise.

The company operates in a competitive market shaped by clinical outcomes, physician adoption, regulatory clearances, procedure volumes, and demand for minimally invasive aesthetic treatments. Its commercial strategy depends on expanding surgeon training, demonstrating safe and effective use of its platforms, and increasing recurring sales of disposable products. For investors, Apyx is primarily a specialized medical device company tied to the growth of energy-based aesthetics and surgical technology.